GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy
GW Pharmaceuticals can now boast about its fifth straight successful Phase III trial for its cannabinoid drug Epidiolex.
Researchers for the biotech said Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
